Evidence map›Paper›PMID 31149044›Full record

ArticleTheranostics2019

Inhibition of protein disulfide isomerase in glioblastoma causes marked downregulation of DNA repair and DNA damage response genes.

Shili Xu, Yajing Liu, Kai Yang, Hanxiao Wang, Andrea Shergalis, Anahita Kyani, Armand Bankhead, Shuzo Tamura, Suhui Yang, Xi Wang and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Thioredoxin Domain Containing 5 (TXNDC5): Friend or Foe?Current issues in molecular biology · 2024
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Shili XuDepartment of Medicinal Chemistry, College of Pharmacy, Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
Yajing LiuRadiation Oncology, Rogel Cancer Center, Center for RNA, University of Michigan, Ann Arbor, MI 48109, USA.
Kai YangNational Laboratory of Biomacromolecules, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
Hanxiao WangRadiation Oncology, Rogel Cancer Center, Center for RNA, University of Michigan, Ann Arbor, MI 48109, USA.
Andrea ShergalisDepartment of Medicinal Chemistry, College of Pharmacy, Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
Anahita KyaniDepartment of Medicinal Chemistry, College of Pharmacy, Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
Armand BankheadDepartment of Biostatistics, University of Michigan, Ann Arbor, MI 48109, USA.
Shuzo TamuraDepartment of Medicinal Chemistry, College of Pharmacy, Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
Suhui YangDepartment of Medicinal Chemistry, College of Pharmacy, Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
Xi WangNational Laboratory of Biomacromolecules, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
Chih-Chen WangNational Laboratory of Biomacromolecules, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
Alnawaz RehemtullaRadiation Oncology, Rogel Cancer Center, Center for RNA, University of Michigan, Ann Arbor, MI 48109, USA.
Mats LjungmanRadiation Oncology, Rogel Cancer Center, Center for RNA, University of Michigan, Ann Arbor, MI 48109, USA.
Nouri NeamatiDepartment of Medicinal Chemistry, College of Pharmacy, Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
Chinese Academy of Sciences · CNInstitute of Biophysics · CNUniversity of Chinese Academy of Sciences · CNUniversity of Michigan–Ann Arbor · US

Funding

Efficacy of PDI inhibitors in glioblastomaR01CA193690 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI NEAMATI, NOURI, REHEMTULLA, ALNAWAZ · 2015 to 2019
$2.4M
NCI NIH HHS R01 CA193690
6 · The paper itself

Abstract

Aberrant overexpression of endoplasmic reticulum (ER)-resident oxidoreductase protein disulfide isomerase (PDI) plays an important role in cancer progression. In this study, we demonstrate that PDI promotes glioblastoma (GBM) cell growth and describe a class of allosteric PDI inhibitors that are selective for PDI over other PDI family members.

Indexed as

Down-RegulationAnimalsAntineoplastic AgentsCell Line, TumorCell SurvivalDisease Models, AnimalDNA DamageDNA RepairDrug Evaluation, PreclinicalEnzyme InhibitorsGlioblastomaHumansMiceMutagenesis, Site-DirectedNeoplasm TransplantationProtein BindingAntineoplastic AgentsEnzyme InhibitorsProtein Disulfide-Isomerasesallosteric inhibitioncancerDNA repairdrug discoveryProtein disulfide isomerase

Identifiers

PMID31149044
PMCPMC6531306
OpenAlexW2935940369

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.